As recent researches suggested,the continuous infusion and novel targeted medicines have been expected to improve the outcome of patients with aggressive B-cell non-Hodgkin's lymphoma.Nevertheless,it does not improve the curative effect by increasingly intensive dosage.Patients with aggressive T-cell non-Hodgkin's lymphoma have present better prognosis recently,which is attributed to better efficacy of the modified regimens in patients with NK/T cell lymphoma.Multiple genetic abnormalities are implicated in poorer prognosis in patients with aggressive T-cell non-Hodgkin's lymphoma.Non-myeloablative allogeneic stem cell transplantation and new targeted drugs have improved the curative effects.Radiotherapy with modern technology also is expected to become an important means to improve outcomes of aggressive non-Hodgkin's lymphoma.